new approaches to optimizing the risk/benefit ratio for the patient by improving efficacy without sacrificing specificity include the use of synergistic combinations of plasminogen activators , mutants of t-pa and scu-pa , chimeric molecules , and antibody-targeted thrombolytic agents .
C0032144
plasminogen activators
C0032143
t-pa